{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:09:36Z","timestamp":1775628576282,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pralatrexate, the first United States Food and Drug Administration (FDA)-approved selective antifolate agent for relapsed\/refractory peripheral T cell lymphoma (PTCL), has an incompletely defined postmarketing safety profile. In this study, we systematically assessed the characteristic spectrum of pralatrexate-related adverse events (AEs) by integrating FDA Adverse Event Reporting System (FAERS) data to improve the safety evidence for this drug and provide scientific support for optimizing clinical risk management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A primary suspected drug-related AE analysis set was constructed following a standardized data cleaning process based on all AE reports from the FAERS database from the first quarter of 2004 through the first quarter of 2025. Signal detection analysis was performed using four algorithms, including the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms. Subgroup analyses were performed for sex, age, and report type categories to explore differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,241 AE reports were extracted from 563 patients using pralatrexate. Patients were predominantly male (58.44%) and aged \u226565 years (45.65%). AEs primarily affected the gastrointestinal, hematopoietic, and integumentary systems. \u201cGeneral disorders and administration site conditions\u201d was the most frequently reported system organ class (N = 354, 15.80%). We detected 84 positive signals, including expected AEs such as mucositis, myelosuppression, skin reaction, and abnormal liver function, as well as several potential new risk signals including hypochloremia, increased platelet counts, prolonged activated partial thromboplastin time, and intestinal ischemia. Mucositis and hematologic toxicity were the primary factors leading to severe outcomes such as death, life-threatening conditions, and hospitalization. The median time to onset of pralatrexate AEs was 16 days (interquartile range, 6\u201359 days), and the Weibull distribution test was consistent with the early failure type. Subgroup analyses showed that the safety profile of pralatrexate was generally consistent between sexes, but risk of toxic epidermal necrolysis was significantly higher in female patients (reporting odds ratio = 5.14, 95% confidence interval: 1.06\u201324.79). In addition, AEs showed a significant age-related relationship, with mucosal injury and metabolic disorders predominating in patients aged \u226565 years, whereas malignant neoplasm progression and abnormal liver function were more common in those aged &amp;lt;65 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study elucidated the safety profile of pralatrexate in real-world settings, validating its established adverse reactions and identifying novel potential AEs. Our findings suggest that clinicians should implement personalized monitoring on the basis of patient sex and age, with a particular emphasis on mucosal toxicity and metabolism-related AEs in patients \u226565 years old. Furthermore, the adverse reaction spectrum of pralatrexate may be broader than previously recognized, necessitating further investigation to optimize medication safety management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1773445","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:32:39Z","timestamp":1775626359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world pharmacovigilance analysis of pralatrexate using the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Municipal Health Commission Key Laboratory for Translational Research in Integrated Chinese and Western Medicine Oncology Diagnosis and Treatment","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Municipal Health Commission Key Laboratory for Translational Research in Integrated Chinese and Western Medicine Oncology Diagnosis and Treatment","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Municipal Health Commission Key Laboratory for Translational Research in Integrated Chinese and Western Medicine Oncology Diagnosis and Treatment","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonglang","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Municipal Health Commission Key Laboratory for Translational Research in Integrated Chinese and Western Medicine Oncology Diagnosis and Treatment","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Municipal Health Commission Key Laboratory for Translational Research in Integrated Chinese and Western Medicine Oncology Diagnosis and Treatment","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqi","family":"Nian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]},{"name":"Chongqing Municipal Health Commission Key Laboratory for Translational Research in Integrated Chinese and Western Medicine Oncology Diagnosis and Treatment","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-024-01560-7","article-title":"Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma","volume":"17","author":"Chang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1097\/CM9.0000000000003410","article-title":"Immune aging and infectious diseases","volume":"137","author":"Chen","year":"2024","journal-title":"Chin. Med. J. Engl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bjh.19433","article-title":"Long-term outcome of peripheral T-cell lymphomas: ten-Year follow-up of the international prospective T-cell project","volume":"205","author":"Civallero","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41568-025-00858-z","article-title":"Ageing, immune fitness and cancer","volume":"25","author":"Dolan","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann. Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2018.0613","article-title":"Tumor lysis syndrome","volume":"4","author":"Gupta","year":"2018","journal-title":"JAMA Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11523-019-00630-y","article-title":"Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study","volume":"14","author":"Hong","year":"2019","journal-title":"Target Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.cell.2025.03.011","article-title":"From geroscience to precision geromedicine: understanding and managing aging","volume":"188","author":"Kroemer","year":"2025","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1046\/j.1440-1622.2001.02104.x","article-title":"Management of extravasation injuries","volume":"71","author":"Kumar","year":"2001","journal-title":"ANZ J. Surg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"161586361","DOI":"10.3389\/fimmu.2025.1586361","article-title":"Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. food and drug administration drug approval summary","volume":"16","author":"Malik","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B16","unstructured":"Outline of the law for partial revision of the pharmaceutical affairs law (act No.84 of 2013)\n          \n          \n          2013"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J. Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/clpt.2009.80","article-title":"A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-hodgkin's or hodgkin's lymphoma","volume":"86","author":"Mould","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O'Connor","year":"2007","journal-title":"Br. J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1080\/10428194.2017.1306642","article-title":"Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use","volume":"58","author":"O'Connor","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41568-023-00651-w","article-title":"Removing barriers to address sex differences in anticancer drug toxicity","volume":"24","author":"Ozdemir","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/fon.12.168","article-title":"Pralatrexate: treatment of T-cell non-hodgkin's lymphoma","volume":"9","author":"Parker","year":"2013","journal-title":"Future Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.critrevonc.2008.10.011","article-title":"Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets","volume":"71","author":"Rodriguez","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"161558868","DOI":"10.3389\/fphar.2025.1558868","article-title":"A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-hodgkin's lymphoma","volume":"12","author":"Toner","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B29","unstructured":"FDA\n          \n          \n          2020"},{"key":"B30","unstructured":"Highlights of prescribing information these highlights do not include all the information needed to use methotrexate injection safely and effectively\n          \n          \n          2024"},{"key":"B31","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin. Experimental Rheumatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3969\/j.issn.1672-5433.2015.10.005","article-title":"An introduction of American OpenFDA of public health project","volume":"12","author":"Xu","year":"2015","journal-title":"China licens. Pharm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1559447","DOI":"10.3389\/fphar.2025.1559447","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.semcancer.2024.10.006","article-title":"Immunosenescence in digestive system cancers: mechanisms, research advances, and therapeutic strategies","author":"Zhang","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"59101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event reporting system (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1773445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:32:42Z","timestamp":1775626362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1773445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":36,"alternative-id":["10.3389\/fphar.2026.1773445"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1773445","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"article-number":"1773445"}}